Full history for every metric is available with a Kvantra account
Aptinyx Inc. (APTX)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 5 | 7 | 4 | 2 | 1 | 0 | 0 |
| Operating profit | $m | -63 | -64 | |||||
| Net profit | $m | -32 | -53 | -57 | -50 | -75 | -65 | -67 |
| EPS reported | $ | -0.95 | -0.99 | |||||
| Operating cashflow per share | $ | -0.88 | -0.88 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.88 | -0.88 | |||||
| Free cash flow | $m | -60 | -55 | |||||
| Net debt | $m | -31 | -19 | |||||
| Book value equity | $m | 38 | 18 | |||||
| Book value per share | $ | 0.57 | 0.27 | |||||
| Number of shares | m | 67.72 | 67.72 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.50 | 0.36 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.32 | -0.12 | |||||
| EV/EBITDA LTM | x | 0.19 | 0.21 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -335.67% | -997.56% | |||||
| FCF Yield | % | -308.93% | -847.98% | |||||
| Quality | ||||||||
| ROE | % | -169.38% | -97.49% | |||||
| ROIC | % | -97.89% | -97.89% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.40 | -2.03 | |||||
| Net Debt/EBITDA | x | 0.51 | 0.51 | |||||
| EBIT/Net interest | x | -20.72 | -20.72 | |||||
| Net debt/market cap | % | -162.02% | -299.58% | |||||
| Net debt/Equity | x | -0.82 | -1.07 | |||||
| Gross debt/equity | x | 0.65 | 1.49 | |||||
Company overview
Aptinyx Inc. is a biopharmaceutical company in the clinical development stage, focused on identifying, advancing, and commercializing innovative, proprietary, synthetic small-molecule therapies for neurological and central nervous system disorders. Its primary drug candidate, NYX-2925, is currently in Phase II clinical trials for addressing painful diabetic peripheral neuropathy, and also in Phase IIb evaluation for fibromyalgia. Additionally, the company is developing NYX-783, an N-methyl-D-aspartate receptor (NMDAr) modulator, which is undergoing Phase IIb clinical trials for post-traumatic stress disorder (PTSD). Another NMDAr modulator, NYX-458, is in Phase II clinical study, targeting cognitive impairment related to Parkinson's disease. Aptinyx Inc. also holds a research collaboration agreement with Allergan plc. The company was founded in 2015 and is based in Evanston, Illinois.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aptinyx Inc. (APTX)
Aptinyx Inc. is a biopharmaceutical company in the clinical development stage, focused on identifying, advancing, and commercializing innovative, proprietary, synthetic small-molecule therapies for neurological and central nervous system disorders. Its primary drug candidate, NYX-2925, is currently in Phase II clinical trials for addressing painful diabetic peripheral neuropathy, and also in Phase IIb evaluation for fibromyalgia. Additionally, the company is developing NYX-783, an N-methyl-D-aspartate receptor (NMDAr) modulator, which is undergoing Phase IIb clinical trials for post-traumatic stress disorder (PTSD). Another NMDAr modulator, NYX-458, is in Phase II clinical study, targeting cognitive impairment related to Parkinson's disease. Aptinyx Inc. also holds a research collaboration agreement with Allergan plc. The company was founded in 2015 and is based in Evanston, Illinois.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free